OTCMKTS:SIGY Sigyn Therapeutics (SIGY) Stock Price, News & Analysis $0.04 +0.01 (+37.15%) As of 09:49 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Sigyn Therapeutics Stock (OTCMKTS:SIGY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sigyn Therapeutics alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.02▼$0.0952-Week Range$0.01▼$5.00Volume100 shsAverage Volume53,227 shsMarket Capitalization$100.33 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California. Read More Receive SIGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigyn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SIGY Stock News HeadlinesSigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTEApril 2, 2026 | finance.yahoo.comSigyn Therapeutics Delays Annual SEC FilingMarch 31, 2026 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 19 at 1:00 AM | InvestorPlace (Ad)Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory DiseasesMarch 24, 2026 | finance.yahoo.comSigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale InitiativesMarch 13, 2026 | finance.yahoo.comSigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate InitiativesJanuary 15, 2026 | finance.yahoo.comThe Emergence of Blood Purification Devices to Treat Cardiovascular DiseaseJanuary 7, 2026 | theglobeandmail.comSigyn Therapeutics Reports Third Quarter Financial Results and Subsequent Introduction of CardioDialysis(TM)November 14, 2025 | finance.yahoo.comSee More Headlines SIGY Stock Analysis - Frequently Asked Questions How have SIGY shares performed this year? Sigyn Therapeutics' stock was trading at $1.7099 on January 1st, 2026. Since then, SIGY shares have decreased by 97.7% and is now trading at $0.0395. How were Sigyn Therapeutics' earnings last quarter? Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) announced its quarterly earnings results on Tuesday, December, 2nd. The company reported $0.49 EPS for the quarter. How do I buy shares of Sigyn Therapeutics? Shares of SIGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sigyn Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sigyn Therapeutics investors own include Rocket Lab (RKLB), Archer Aviation (ACHR), Atlas Lithium (ATLX), OriginOil (OCLN), bluebird bio (BLUE) and BlackSky Technology (BKSY). Company Calendar Last Earnings12/02/2025Today5/19/2026Next Earnings (Estimated)5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolOTCMKTS:SIGY CIK1642159 Webwww.sigyntherapeutics.com Phone(619) 353-0800FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.34 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-3,743.20% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.78) per share Price / Book-0.01Miscellaneous Outstanding Shares2,540,000Free Float548,000Market Cap$100.33 thousand OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:SIGY) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigyn Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigyn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
